Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Actavis, Inc. (ACT - Analyst Report) recently re-launched Vestura (3 mg drospirenone and 0.02 mg ethinyl estradiol), the company’s generic version of Bayer’s (BAYRY - Analyst Report) oral contraceptive, Yaz. Actavis decided to re-launch Vestura following a favorable ruling by the US Court of Appeals for the Federal Circuit regarding the RE '564 patent.

Vestura was initially launched in Jan 2012. However, Actavis had to withdraw the product from the market when the US District Court for the District of Nevada found the RE '564 patent to be valid. Actavis had appealed the ruling in the Federal Circuit which found the patent to be invalid.

Vestura is approved for the prevention of pregnancy and the treatment of moderate acne in women at least 14 years old only if the patient is willing to use an oral contraceptive for birth control.

Bayer recorded Yaz/Yasmin/Yasminelle sales of €1,045 million in 2012. Actavis estimates that Yaz sales, branded and generic, for the 12 months ended Feb 28, 2013 were about $347 million in the US.

Indian company Lupin is also looking to launch its generic version of Yaz – the company’s generic version has yet to gain approval from the US Food and Drug Administration (FDA). Lupin is currently working on its commercialization plan for generic Yaz while awaiting FDA approval.

Actavis currently carries a Zacks Rank #3 (Hold). The favorable court ruling is a positive for the company.

Companies in the generic space that currently look better-positioned include Mylan, Inc. (MYL - Analyst Report) and Akorn, Inc. (AKRX - Snapshot Report). Both are Zacks Rank #2 (Buy) stocks.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GROUP DXYN 15.84 +7.90%
BOFL HOLDING BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%